Abstract
One of the major reasons why depressed patients fail their treatment course is the existence of the blood-brain barrier (BBB), which prevents drugs from being delivered to the central nervous system (CNS). In recent years, nasal drug delivery has achieved better systemic bioavailability and activity in low doses in antidepressant treatment. In this review, we focused on the latest strategies for delivery carriers (or formation) of intranasal antidepressants. We began this review with an overview of the nasal drug delivery systems, including nasal drug delivery route, absorption mechanism, advantages, and limitations in the nasal drug delivery route. Next, we introduced the development of nasal drug delivery devices, such as powder devices, liquid-based devices, and so on. Finally, intranasal delivery carriers of antidepressants in clinical studies, including nanogels, nanostructured lipid, liposomes nanoparticles, nanoemulsions/microemulsion, were summarized. Moreover, challenges and future perspectives on recent progress of intranasal delivery carriers in antidepressant treatments were discussed.
Introduction
Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings, physical well-being, and circadian rhythm. Depression has become the leading cause of disability worldwide and is a significant global health burden (Glahn et al., ). What worries us is that, although the dozens of antidepressant drugs, which are approved by the Food and Drug Administration (FDA) as shown in Table 1, have demonstrated efficacy in clinical practice, many depressed patients do not respond to the first-line pharmacological treatment and even fail following several pharmacological interventions (Oleary et al., 2015).
Table 1
| Classifications | Drug name | Active ingredients | FDA approved year | Formations |
|---|---|---|---|---|
| Selective serotonin reuptake inhibitors (SSRIs) | PROZAC | Fluoxetine | 1987 | Capsule |
| CELEXA | Citalopram | 2000 | Tablet | |
| PAXIL | Paroxetine | 1992 | Tablet | |
| VIIBRYD | Vilazodone | 2011 | Tablet | |
| Serotonin norepinephrine reuptake inhibitors (SNRIs) | EFFEXOR | Venlafaxine | 1993 | Tablet |
| CYMBALTA | Duloxetine | 2004 | Tablet | |
| DESVENLAFAXINE | Desvenlafaxine | 2013 | Tablet | |
| FETZIMA | Levomilnacipran | 2013 | Capsule | |
| Tricyclic antidepressants (TCAs) | TOFRANIL | Imipramine | 1982 | Injection |
| PAMELOR | Nortriptyline | 1982 | Solution | |
| ELAVIL | Amitriptyline | 1982 | Tablet | |
| Monoamine oxidase inhibitors (MAOIs) | NARDIL | Phenelzine | 1982 | Tablet |
| PARNATE | Tranylcypromine | 1985 | Tablet | |
| Other | REMERON | Mirtazapine | 1997 | Tablet |
| WELLBU-TRIN | Bupropion | 2002 | Tablet |
FDA approved antidepressants.
Why is this the case? One of the major reasons patients fail in their treatment course is the existence of the blood-brain barrier (BBB), which is the bottleneck of drug delivery for the central nervous system (CNS). BBB, which is mainly composed of cerebral endothelial cells (CECs) that constitute a selective barrier covering the inner surface of cerebral capillaries, is the major site of blood–CNS exchange, maintaining the homeostasis of the CNS (Bernacki et al., ; Abbott et al., ). CECs heavily determine the BBB permeability of most circulating compounds. Efflux transmembrane proteins, expressed in endothelial cerebral cells, and particularly those from the ATB-binding cassette family, which mainly include P-glycoprotein (P-gp) and breast-cancer-resistant protein (BCRP), are included in the BBB (Bicker et al., ; Tang et al., 2017). The ability to cross this biological barrier has been the determining characteristic for the effectiveness of CNS drugs. To date, there are three strategies used to deliver therapeutics across the barrier of the BBB (Sun et al., 2017; Aderibigbe and Naki, ; Saeedi et al., 2019; Zhang M. et al., 2019; Shi et al., 2020): (1) by other routes of drug delivery including drug-encapsulated wafers inserted in the tumor cavity, facial intradermal injection, and drugs administered via the nasal cavity; (2) by interrupting the BBB using surfactants and hyperosmotic agents, cell-penetrating peptides, or magnetic nanoparticle-induced hyperthermia; and (3) by endogenous transporters and receptors for enhanced neural non-invasive penetration of drugs. Although antidepressant drugs have recently been identified as substrates, inhibitors, and inductors of P-gp (Obrien et al., 2012), an effective therapy with antidepressant drugs depends on drug concentrations and bioactivity, but conventional oral and parenteral therapies are limited due to the difficulty in crossing the BBB (Vitorino et al., 2019). Nasal mucosa as a potential administration route has achieved faster and higher levels of drug absorption because more compounds could permeate and administrate due to the high permeability, high vasculature, low enzymatic environment of nasal cavity, and avoidance of the hepatic first pass metabolism (Jadhav et al., ; Alagusundaram et al., ). In recent years, nasal drug delivery has achieved better systemic bioavailability and activity in low doses because the nasal route avoids the hepatic first pass elimination associated with the oral delivery. Intranasal drug delivery proposed a reliable method to bypass the BBB. Due to a direct connection between the brain and the nasal cavity, intranasal administration is the preferred route from the outside environment. Moreover, intranasal formulations have been developed to degrade enzymatic ion and improve the pharmacological effects. More and more pharmaceutical scientists and clinicians have given increasing attention to drug delivery via the nasal route, as shown in Table 2 (Kanojia et al., 2017; Ambrus et al., ; Shetty et al., 2020).
Table 2
| Classifications | Common materials | Example | References |
|---|---|---|---|
| Nanogels | Lutrol F127 | Venlafaxine | Bhandwalkar and Avachat, |
| Chitosan- glycerophosphate | Doxepin | Naik and Nair, 2014 | |
| Chitosan-Pluronic and HPMC | Tramadol HCl | Kaur et al., 2014 | |
| Nanostructured lipid | Solid lipid (glyceryl monostearate) and liquid lipid (capryol PGMC) | DLX | Alam et al., |
| Liposomes | Mixture of egg phosphatidylcholine (EPC) and cholesterol (chol) | Piperine | Priprem et al., 2011 |
| Nanoparticles | Chitosan nanoparticles | Venlafaxine | Haque et al., |
| Alginate chitosan nanoparticles (VLF AG-NPs) | Venlafaxine | Haque et al., | |
| PLGA-chitosan nanoparticles | Desvenlafaxine | Tong et al., 2017 | |
| Nanoemulsions /microemulsion | Capmul MCM, Solutol HS 15, and propylene glycol | Paroxetine | Pandey et al., 2016 |
| Capmul MCM (O-7% w/w) –TRIN | Mirtazapine | Thakkar et al., 2013 |
Preparation materials for several common delivery carriers of intranasal antidepressants.
In this review, we focused on the latest strategies of delivery carriers of intranasal antidepressants (Scheme 1). We began this review with an overview of the nasal drug delivery systems, including nasal drug delivery route, absorption mechanism, and advantages and limitations in nasal drug delivery route. Next, we introduced the development of nasal drug delivery devices, such as powder devices, liquid-based devices, and so on. Finally, intranasal delivery carriers of antidepressants in clinical studies, including nanogels, nanostructured lipid, liposomes nanoparticles, and nanoemulsions/microemulsion, were summarized. Moreover, challenges and future perspectives on recent progress of intranasal delivery carriers in antidepressant treatment were discussed.
Scheme 1
Nasal Drug Delivery Systems
Nasal Drug Delivery Route
The nasal route has gained attention as it is a direct non-invasive way to transport drugs to the brain which cannot be transferred via the oral route. To date, olfactory and trigeminal nerves have been shown to be safe and effective pathways to deliver therapeutic agents to brain (Figure 1).
Figure 1
The olfactory pathway is composed of the olfactory epithelium, lamina propria, and olfactory bulb. Three types of cells, neuronal cells, progenitor cells, and supporting cells belong to the olfactory epithelium and are connected by tight junctions. An information pathway to the brain is built by neuronal cells which start from the olfactory bulb in the CNS to the olfactory epithelium in the nasal cavity (Leopold, 1988). Due to the constant motion between basal cells and neural cells, the delivery ability of drugs to the brain was enhanced (Caggiano et al., ). Lamina propria, which consists of blood vessels, mucus secreting glands, olfactory axons, and a maxillary branch of trigeminal nerve, lies on the nasal epithelium (Brand, ; Choi et al., ; He et al., ). The olfactory bulb is used for direct nasal delivery of drugs for its distribution in different regions of the brain, such as the piriform cortex, amygdala, and hypothalamus (Khan et al., 2017).
The trigeminal pathway is another important route for delivery of therapeutic agents to the brain. The trigeminal nerve with three branches, including the ophthalmic nerve, maxillary nerve, and mandibular nerve, control the respiratory region of the nasal cavity and sensation of the nasal cavity. Among them, ophthalmic and maxillary nerves bring the information from the nasal cavity to the CNS by controlling the nasal mucosa. So, numerous drug delivery systems for the brain or nerves usually use these two branches as a target for the delivery of drugs (Johnson et al., ; Venereau et al., 2016). Drugs enter the brainstem through pons by the trigeminal nerve controlling the nasal cavity and then travel to caudal and rostral parts of brain so that transport of drugs to the brain is achieved. Because not only the olfactory pathway but also the trigeminal pathway could deliver drugs to the rostal area of the brain, it difficult to distinguish when drugs are intranasally administered to the brain by nasal administration (Thorne et al., 2004; Johnson et al., ) as shown in Figure 2.
Figure 2
Cerebrospinal fluid (CSF) in the subarachnoid space and nasal lymphatics provide a pathway for therapeutics to both CSF and other areas of the CNS (Dhuria et al., ). Some radiolabeled tracers were injected into the CSF in cerebral ventricles or subarachnoid space drain to olfactory bulbs, which then traveled into channels and entered the nasal lymphatic system and cervical lymph nodes (Johnston et al., ), which demonstrated the reach of drugs to the CNS after intranasal drugs moved from the nasal cavity to the CSF, the brain interstitial spaces, and perivascular spaces. Moreover, the distribution of neurotherapeutics in CSF also proves the mechanism of nose-to-brain drugs (During et al., ).
Mechanism of Drug Nasal Delivery and Absorption
The principal process in the delivery and absorption of a drug by the nasal cavity route is through the mucus. Mucin, which is formed from mucus, is a protein that has the potential to bind with solutes and thus affect the diffusion process. There are numerous mechanisms for nasal delivery and absorption through the mucosa, including paracellular and transcellular routes (Duvvuri et al., ). Paracellular transport is an inverse correlation between intranasal absorption and the molecular weight of water-soluble compounds. When a molecular weight is >1,000 Daltons, drugs showed poor bioavailability (Huang et al., ; Alex et al., ; Li Y. et al., 2018). The second mechanism is a transcellular process and is responsible for the transport of lipophilic drugs that show a rate dependency on their lipophilicity (Kangmieler et al., 2014; Proschak et al., 2017). As discussed above, to enhance bioavailability, permeation enhancers are necessary (Wang and Chow, 2014; Yamamoto et al., 2017). Permeation enhancers would induce reversible modifications on the structure of the epithelial layer by modifying the phospholipid bilayer (Dhuria et al., ; Mouez et al., 2014).
Advantages and Limitations of Nasal Drug Delivery Route
An intranasal drug delivery system offers a non-invasive, effective, reliable, direct, and alternative route to the CNS via the neural connections between the nasal mucosa and the brain (Graff and Pollack, ), which is one of the most permeable and highly vascularized sited for drug administration and the onset for therapeutic action (Illum, ; Thorne and Frey, 2001). Some distinctive advantages for drug delivery are as follows: (Fortuna et al., ; Kumar et al., 2016; Kashyap and Shukla, 2019; Nidhi et al., 2019; Kaneko et al., 2020; Wang et al., 2020) (1) A large surface for drug absorption; (2) Convenience and good patient compliance; (3) Rapid attainment of therapeutic drug levels in the blood; (4) High drug permeability, especially for lipophilic and low molecular weight drugs; (5) Avoidance of harsh environmental and gastrointestinal conditions; (6) Bypassing of the hepatic first-pass metabolism; (7) Potential direct drug delivery to the brain along the olfactory nerves; (8) Direct contact site for vaccines with lymphatic tissues; (9) Convenient for patients in long-term therapy; and (10) An alternative route for drugs with poor stability in fluids. In the nasal epithelium, the therapeutic agents are delivered to the olfactory bulb and brainstem, and disperse to other CNS areas via pulsatile flow within the perivascular spaces of cerebral blood vessels which contributes to drug absorption. It is almost equal to intravenous injections in some instances, owing to the unique direct connection between the brain and the nasal cavity (Angeli et al., ; Musumeci and Bonaccorso, 2019; Craft et al., ). Intranasal administration is the only route that connects the brain with the outside environment (Mistry et al., 2009), which has received attention due to its wide drug delivery potential, including nucleotides, peptides, proteins, and even stem cells. Moreover, the nasal route of drug delivery includes both local and systemic drug delivery. A wide range of pharmaceutical dosage forms, including solutions, gels, suspensions, emulsions, liposomes, and microparticles administered via nasal route (Jullaphant et al., 2009; Kitiyodom et al., 2019; Lengyel et al., 2019; Salade et al., 2019), achieved an enhanced targeting ability and reduced systemic side-effects.
However, some vital factors and physicochemical properties influence the nasal absorption of drugs: (1) Physiochemical properties of the drug, including molecular weight, particle size, lipophilic-hydrophilic balance, and enzymatic degradation; (2) Nasal effect, including membrane permeability, environmental pH, mucociliary clearance, etc.; and (3) Delivery effect, including formulation, drugs distribution and deposition, and viscosity of the formulation (Alagusundaram et al., ; Chaturvedi et al., ; Bakri et al., ; Inoue et al., ). For example, some polar drugs or macromolecules are not absorbed in high enough concentrations for their poor membrane permeability, rapid clearance, and enzymatic degradation within the nasal cavity. And the nasal mucosa and physiological and anatomical factors, including nasal blood flow, enzymatic degradation, mucociliary clearance, the physical condition of the nose, including nasal atrophic rhinitis and severe vasomotor rhinitis, could also reduce the capacity of nasal drug absorption and bioavailability as Figure 3 (Sintov et al., 2010; Qian et al., 2014; Mansuri et al., 2016; Rohm et al., 2017; Inoue et al., ; Rohrer et al., 2018; Akel et al., ; Badhe and Nipate, ). These limitations must be addressed in the design of drug absorption by the nasal route.
Figure 3
Nasal Drug Delivery Devices
It should be noted that efficient and novel nasal drug delivery devices used for direct transport of drugs from nose to brain is another important strategy for the improvement of diagnosis and treatment effect, which help drugs to be transported to the brain via the olfactory/trigeminal pathway. Some devices, including droppers, syringes, pressurized meter dose inhalers, Breathe Powered Bi-directional nasal devices, and pressurized olfactory delivery devices, were adopted in clinical treatment and were also categorized into devices with liquid, powder, and semisolid formulations (Djupesland, ; Erdő et al., ). The right delivery system depended on the type of drug formulation. Powder formulations with high stability often stick to the nasal mucosa before it is cleared. Liquid formulations are the oldest, cheapest, and simplest method. Popular nasal sprays spread easily and deposit in the olfactory region. The spray would distribute in the nasal cavity through nasal mucociliary clearance. But the limitation of nasal drops or spray devices depends on the self-administration technique.
Powder Devices
Compared with liquid (solution or suspension) and gel formulations of drugs, powder particles are stable and not easily dissolved so they can remain in the nasal mucosa for a long time. Moreover, because of free preservatives, powder dosages could be administrated in a large dose and prevent microbial contamination. Deposition and absorption of a powder formulation of drugs for nasal delivery depend on many factors, including size and shape of powder particle, flow characteristics, and solubility (Djupesland, ) as shown in Figure 4.
Figure 4
An insufflator composed of straw or tube with drugs could directly deliver drugs to the olfactory region, although usually local anesthetics or decongestants are needed before insufflations delivery. Direct Haler, designed by a Danish company, delivered fine particles into the nasal cavity with lungs exposure. Compared with pressurized metered dose inhalers (pMDI) with poor patient acceptability, insufflators utilized the exhalation force of patients with normal temperatures and was popular. The Direct Haler device exhibited excellent advantages such as being free from contamination and preservatives, priming, and cleaning. Because the Direct Haler's route of drug delivery is from nose to brain, targeting the nasal valve is necessary. Smaller powder particles below 5 μ are used for olfactory absorption to increase the drug deposition to lungs. Bi-Directional technology uses the normal breath processes of the body to deliver drugs in liquid or powder form on the nasal epithelium (Djupesland, ). The nasal valve is a barrier for delivery of drugs because the nasal cavity is narrow. Optinose, a biopharmaceutical company, proposed closed-palate Bi-Directional™ Breath Powered® DDSs, which used an exhale device to target the drug beyond this valve (Djupesland, ; Djupesland et al., ). As we know, oxytocin has already been used for treatment of patients on the autism spectrum, however, a higher dose would lead to adverse effects. Quintana et al. (2015) proposed a randomized four-way crossover trial using a breath powered optinose device to study the relationship between the effect of oxytocin on social cognition with dose. Through this device, a lower dose was observed with a breath powered optinose device to deliver oxytocin across the nasal mucosa to the brain and demonstrated that lower doses are more efficacious than higher in producing a cognitive response.
Dry powder inhalers (DPI), which contain drug particles suspended or dissolved in solvent when they contact the nasal mucosa, deliver small doses to the nasal cavity. Teijin Puvlizer Rhinocort® is the earliest dry powder inhaler on the market. Rhinocort Turbohaler®, Rhinicort Puvlizer®, and Erizas® are three popular nasal dry inhalers used for the treatment of rhinitis (Gomes dos Reis et al., ). Dry powder inhalers are simple in design, cheap, can be operated without medical supervision, and doses range from μg to mg.
Bespak developed Unidose-DP™, resembling Flit Lizer technology, which was composed of a sealed container used for delivering a single shot of a drug. About 95% of the drug was delivered to the nasal cavity and about 60–70% reached the nasal vestibular region (Kaye et al., 2009). SoluVent™ is a powder delivery device and forces the powder to the nasal cavity. Vaccines have been delivered through this device (Huang et al., ). μco™ System was designed by Shin Nippon Biomedical Laboratories for drug absorption and decreased dose requirement. Powder carriers with systemic delivery, low molecular weight, and high molecular weight enhanced safety in clinical treatment (Bell et al., ; Ugwoke et al., 1999). μco™ System was designed by Shin Nippon Biomedical Laboratories. The μco™ carrier technology was based on a mucoadhesive powder drug carrier, which increased drug absorption and decreased doses of drug and provided a high activity and long contact time (Djupesland, ).
Liquid-Based Devices
Catheter-delivered drugs are the simplest method of drug delivery to the nasal cavity through the insertion of a catheter in the nose cavity. This technique is usually accompanied with anesthesia or a sedative to deliver the liquid. Because mucosa is sensitive to the deposition site, it is a major issue with this method of drug delivery. By blowing with the mouth, solution filled in the catheter enters into the nostril by the other end of the catheter in the nose cavity (Trangsrud et al., 2002; Berger et al., ; Djupesland, ).
Drops are another important method of nasal drug delivery for liquid formulations and have been used for decades due to their cost effectiveness and easy manufacture. However, this method risks microbial contamination and chemical instability. Glass droppers are a typical single dose drug delivery, and spray pumps would obtain a multidose administration. However, spray pumps are expensive and often are replaced by cheap disposable pipettes in clinical treatment. Pipettes, especially in treatment for nasal decongestion and irrigation purposes, often replace the drop or spray pump in the European market (Penttilä et al., 2000).
The olfactory epithelium is located in the upper part of the nose and is about 3–10% of the surface area of the nasal cavity between the nose and brain. It is a challenge to deliver therapeutic molecules via the nasal cavity due to its turbinate restriction (Morrison and Costanzo, 1990; Fonseca-Santos et al., ; Brozzetti et al., ). The pressurized olfactory device (POD) of Impel NeuroPharma (Seattle, Washington), containing a suitable tank, compressed air or nitrogen, chlorofluorocarbon (CFC) or hydrofluoroalkane (HFA), used as a propellant and air chamber, was realized to target the drug to the olfactory part of the nasal cavity. POD could transport both liquid and powder formulations through the nasal epithelium. Impel NeuroPharma deliver aqueous and powder forms of cholinergic reactivator (pralidoxime, 2-PAM) by POD with a higher concentration of 2-PAM in the brain (Brunelle et al., ; Bachurin et al., ).
Intranasal Delivery Carriers of Antidepressants In Clinical Studies
Conventionally, drugs that are administered through the intranasal route are in the forms of solutions, suspensions, gels, emulsions, and powders. However, these conventional dosage forms meet many problems, such as a lack of dose precision, high particle size, high viscosity, and lack of drug stability. To enhance patient convenience, adherence, and comfort, alternating drug formulations and routes of administration should be used. As we know, oral and injectable routes of drug delivery result in a relatively well-tolerated therapeutic management, but it isn‘t feasible in all patients. The pharmacokinetic and physicochemical properties of drugs used in intranasal administration and drug properties for antidepressant medications are summarized in Table 3 (Mathias and Hussain, 2010; Bento et al., ). Two important factors, degree of lipophilicity (log P) and absorption of the acid dissociation constant (pKa), would most affect drug intranasal administration. Theoretically, based on these chemical properties, alternative routes of administration for antidepressants depending on different and novel formulations, including nanogels, nanostructured lipid, liposomes nanoparticles, and nanoemulsions/microemulsion, could be explored as drug delivery systems for intranasal delivery (Joshi et al., 2006; Wong et al., 2017; Ding et al., ).
Table 3
| Drug | Adult oral dose | Molecular weight of parent molecule | Log P | Basic pKa |
|---|---|---|---|---|
| Citalopram | 20–40 mg | 324.4 | 3.72 | 9.57 |
| Desvenlafaxine | 50–100 mg | 263.4 | 2.80 | 9.33 |
| Doxepin | 75–300 mg | 279.4 | 3.91 | 9.19 |
| Escitalopram | 10–20 mg | 324.4 | 3.72 | 9.57 |
| Fluvoxamine | 50–300 mg | 318.3 | 2.55 | 9.39 |
| Mirtazapine | 15–45 mg | 265.4 | 3.09 | 8.1 |
| Paroxetine | 20–50 mg | 329.4 | 3.23 | 9.68 |
| Selegiline | 5–30 mg | 187.3 | 3.79 | 7.53 |
| Trazodone | 50–400 mg | 371.9 | 2.42 | 7.52 |
| Venlafaxine | 75–375 mg | 277.4 | 3.02 | 9.27 |
Physicochemical properties of intranasal antidepressants.
Nanogels
Intranasal delivery, as an attractive alternative method, has been used in the treatment of major depressive disorder, social anxiety disorder, generalized anxiety disorder, and panic disorder. However, low residence time of drugs in the nasal cavity would affect absorption and in turn bioavailability of the drug, which has been a crucial problem that must be faced in clinical treatment. That is, the anatomic and physiologic characteristics of nasal mucosa must be considered in the design of nasal dosage forms used for solving the rapid mucocilliary clearance (MCC) (Grinberg et al., ; Patel and Patel, 2017; Li S. et al., 2018; Jiang et al., ; Qiu et al., 2020). Gel as a nasal mucoadhesive has been very attractive due to its fluid-like qualities prior to nasal administration and can easily be administered by drops to allow for accurate drug dosing. Moreover, gelation can be constructed by using thermos-sensitive smart polymers which use sensing with nasal temperature (Dias et al., ; Singh et al., 2013; Naik and Nair, 2014; Gholizadeh et al., ; Zhang Y. et al., 2019). Bhandwalkar and Avachat () reported an in situ mucoadhesive thermoreversible gel used for improving bioavailability of the antidepressant drug, venlafaxine hydrochloride, composed of Lutrol F127 (18%). Mucoadhesive thermoreversible in situ nasal gel enhanced nasal residence time and absorption of venlafaxine hydrochloride across the nasal mucosal membrane to improve bioavailability of the drug as compared with the oral route and administration of an equivalent dose. A thermoreversible biogel system based on chitosan and glycerophosphate for delivery of doxepin to the brain through intranasal administration was also reported (Naik and Nair, 2014). The antidepressant doxepin hydrochloride was doped into the mixture of chitosan and glycerophosphate with polyethylene glycol. The mixture gelled rapidly at 37°C, and returned to sol state upon cooling. The gels showed potential as effective drug delivery methods to the brain via the nose. Moreover, an intranasal chitosan nanoparticles (NPs)-loaded in situ gel, Tramadol HCl, against depression was developed (Kaur et al., 2014). Chitosan nanoparticles (NPs) were prepared by ionic gelation method followed by the addition of developed NPs within the Pluronic and HPMC-based mucoadhesive thermo-reversible gel. Depression induction of forced swim test and various behavioral and biochemical parameters demonstrated that intranasal TRM HCl NP-loaded in situ gels were a promising formulation for the treatment of depression.
Nanostructured Lipid
Nanostructured lipid carriers (NLCs), which are the nanostructured particles produced from the two-phased blend of solid and liquid lipids, have gained increasing attention during the last years. A characteristic feature of the NLC is its controlled “imperfections” nanostructure, which is created by lipid particle matrix as imperfectly as possible by spatially very different molecules being mixed into them. The imperfections in NLC increase drug loading capacity and minimize or avoid drug loss resulted from light,oxidation and hydrolysis. NLC has been used as a delivery carrier of therapeutic substances to the brain (Muchow et al., 2008).
Duloxetine (DLX) is the first class of anti-depressants which ensures rapid and sustained efficacy in treatment of both emotional and physical symptoms of depression. On oral administration of DLX, its bioavailability, kept about 50%, undergoes hepatic first pass metabolism (Martin et al., 2003). Moreover, as we know, the efficacy of antidepressants relies upon their continued presence at the site of action (brain), however, as DLX is an oral as well as intravenous administration, the BBB would restrict the access of antidepressant drugs to the brain, leading to the reduction in dose and side effects (Laffleur and Keckeis, 2020). Alam et al. () reported a nanostructured lipid carrier system of intranasal administration in which the antidepressant drug, duloxetine (DLX), was contained to circumvent the BBB and maintain prolonged release at the site. DLX-NLC was prepared by mixing melted solid lipid (glyceryl monostearate) and liquid lipid (capryol PGMC), after which both of them were homogenized with hot surfactants aqueous solution (80°C pluronic F-68, 1.5%; sodium taurocholate, 0.5%) and lyophilized. The biodistribution studies suggested that DLX-NLC formulation had a better brain targeting efficiency and higher concentration of DLX in the brain by intranasal administration compared with the intravenous administration in the treatment of depression.
Liposomes
To date, two of the most popular pathways to delivery drugs via nasal administration that are also highly lipid-soluble compounds are hydrophilic and semilipophilic substances. However, highly lipid-soluble compounds usually require several steps and are relatively slow. Hydrophilic and semilipophilic substances provide a relatively quick absorption into the cerebrospinal fluid (CSF). Now liposomes have been used as an effective delivery system to the brain, due to particles being entrapped into the compounds and preventing the rapid degradation through the BBB and distribution in the brain tissue (Talegaonkar and Mishra, 2004; Krauze et al., 2006; Ding et al., ). Liposomes could be prepared into nanosize vesicles (20–100 nm) by phospholipids and similar amphipathic lipids. Lipid bilayers of liposomes are similar to membranes in living cells; thus, they can carry lipophilic substances such as drugs within these layers as cell membranes. Specially, because the drug is entrapped in liposomes, a decreased dose of a compound is usually expected (Sharma and Sharma, 1997; Druliskawa and Dorotkiewiczjach, ; Loirapastoriza et al., 2014).
Quercetin, 3,5,7,3′,4′-pentahydroxylflavone, as a bioflavonol, usually found in foods such as onions, apples, tea, and red wines, could exert beneficial actions on the CNS, such as being antianxiety. To apply quercetin for the treatment of antidepressants, some limitations of quercetin must be solved, such as its poor absorption and very low distribution to the brain after oral administration (Dandrea, ; Wang et al., 2016) for rapid metabolism and bypassing of the BBB. The nasal route of quercetin can serve as a potential pathway for systemic drug delivery because of the high degree of vascularization and permeability of the nasal mucosa. Priprem et al. (2008) developed intranasal quercetin liposomes and assessed the anxiolytic and cognitive effects on rats based on lipid thin film formation and extrusion. The lipid thin film was a mixture of egg phosphatidylcholine (EPC) and cholesterol (chol). Due to the semilipophilic character of quercetin, it was mixed to the EPC/chol using a vehicle (water, 50% ethanol, and 50% PEG). Quercetin liposomes showed anxiolytic and cognitive-enhancing effects. Moreover, a lower dose and a faster rate were observed with intranasal quercetin liposomes which exhibited that the intranasal quercetin liposomes were effective in the delivery of quercetin to the central nervous system. Piperine, which encapsulated liposomes for intranasal delivery, was investigated in male Wistar rats (Priprem et al., 2011). Piperine, as a major alkaloid of black long pepper, had been proven to possess various activities, including anti-inflammatory and anti-depressant (Lee et al., 2005; Menneson et al., 2020). A lipid film of EPC and chol was used in the presence of piperine and chloroform. Subsequently, piperine-encapsulated liposomes were prepared. Intranasal liposomes also proved their potential in the delivery of piperine, at a low dose, to exert its antidepressant and cognitive enhancing activities.
Nanoparticles
Among intranasal drug delivery systems, the mucoadhesive chitosan nanoparticles (NPs) possess the ability to reduce the mucociliary clearance, pass through the tight junctions of cells transiently, and provide a drug transport route from the nasal membrane to the brain by the paracellular route because of its particle size, enhanced permeability, and ability to encapsulate various ingredients (Maculotti et al., 2005; Vllasaliu et al., 2010; Chen J. et al., ). Venlafaxine (VLF) is a dual action antidepressant [serotonin and norepinephrine reuptake inhibitors (SNRI)]. Oral therapy of VLF meets some problems, such as slow onset of action and side effects like tachycardia, increased blood pressure, fatigue, headache, dizziness, sexual dysfunction, and low bioavailability (40–45%).
Haque et al. () prepared venlafaxine (VLF)-loaded chitosan nanoparticles (NPs) to enhance the uptake of VLF to the brain via intranasal delivery. One phase which contained a solution of polycation chitosan mixed with another that contained a solution of polyanion sodium tripolyphosphate (TPP) at room temperature and VLF was dissolved into chitosan solution at the drug polymer ratio of 1:1 before the addition of TPP. The brain/blood ratios of VLF for VLF (i.v.), VLF (i.n.), and VLF chitosan NPs (i.n.), were 0.0293, 0.0700, and 0.1612, respectively, at 0.5 h, which indicated a better brain uptake of VLF-chitosan NPs, higher drug transport efficiency (508.59), and direct transport percentage (80.34) of VLF chitosan NPs. In another piece of research, Haque et al. () investigated Venlafaxine-loaded alginate chitosan nanoparticles (VLF AG-NPs) for the treatment of depression via intranasal (i.n.) nose to brain delivery route. Pharmacodynamic studies of the VLF AG-NPs for antidepressant activity were carried out in-vivo by forced swimming test, which indicated that VLF AG-NPs (i.n.) treatment significantly improved the behavioral analysis parameters including swimming, climbing, and immobility. Tong et al. (2017) prepared Desvenlafaxine-loaded PLGA-chitosan nanoparticles by solvent emulsion evaporation technique and the optimized Desvenlafaxine-loaded PLGA-chitosan nanoparticles based on intranasal administration significantly reduced the symptoms of depression. Intranasal Desvenlafaxine PLGA chitosan nanoparticles also enhanced the Desvenlafaxine in brain together with their brain/blood ratio at different time points, which demonstrated its better efficacy in treatment of depression. Singh et al. (2015) presented the study of thiolated chitosan nanoparticles (TCNs) which were synthesized by the ionic gelation method, to enhance the nasal delivery of selegiline hydrochloride for effective treatment of depression. In the evaluation of drugs on animals, selegiline hydrochloride—TCNs successfully attenuated oxidative stress and restored the activity of the mitochondrial complex. In an evaluation of behavioral parameters, TCNs successfully restored the impaired locomotor activity and normal sucrose consumption was found on treatment. TCNs seemed to be promising carriers for nose-to-brain delivery in the evaluation of antidepressant activity.
Nanoemulsions /Microemulsion
Intranasal delivery of drugs allows the drug to directly enter the brain by bypassing the BBB and avoids extensive hepatic and intestinal metabolism. This route has been a convenient and reliable route. Several new formulations are used to deliver drugs to the brain by olfactory, neuronal, and trigeminal pathways. Nanoemulsions are a promising and novel formulation to deliver lipophilic drugs to the brain through the intranasal route, which is an optically isotropic and thermodynamically stable system composed of oil, water, and surfactant (and/or co surfactant) (Mehta et al., 2008). Due to its high solubilization of lipophilic drugs, stability, ease of preparation, and handled stabilization of hydrolytically susceptible compounds, it provided the advantages of bioacceptability, biodegradability, and rapid uptake by the brain (Abouhussein et al., ; Pires and Santos, 2018). Many drugs, including Sumatriptan (Vyas et al., 2006a; Ganger and Schindowski, ), Zolmitriptan (Vyas et al., 2005; Islam et al., ), Cabergoline (Sharma et al., 2009; Pires and Santos, 2018), Clonazepam (Vyas et al., 2006b; Costa et al., ), Nimodipine (Zhang et al., 2004), Tacrine (Jogani et al., ), and Diazepam (Li et al., 2002), have been administered via the nasal route in the form of microemulsion (Mason et al., 2006; Jones et al., 2017; Singh et al., 2017; Sindhu et al., 2018). Pandey et al. (2016) developed a paroxetine-loaded nanoemulsion (o/w type) for direct nose-to-brain delivery. Nanoemulsions were constructed by the spontaneous emulsification technique using oil phase, including Capmul MCM, Solutol HS 15, and propylene glycol, surfactant and co-surfactant, for a delivery system via the nasal route to treat depression. Intranasal treatment of depressed rats with paroxetine nanoemulsion significantly improved the behavioral activities in comparison to oral paroxetine control groups. Biochemical estimation results suggested that the paroxetine-loaded nanoemulsion was effective in enhancing the depressed levels of glutathione and decreasing the elevated levels of thiobarbituric acid reactive substances (TBARS). Thakkar et al. (2013) prepared mirtazapine microemulsion for intranasal delivery microemulsions (MME-26% w/w, mirtazapine) through completely dissolving mirtazapine in a mixture of oil Capmul MCM (O-7% w/w), surfactant Tween-80 (S-33.75% w/w), co-surfactant, and Polyethylene Glycol 400 (CoS-11.25% w/w). Pharmacokinetics, swim tests, locomotor activity, maze tests, and brain/blood uptake ratios all demonstrated a more rapid and a larger extent of transport of mirtazapine into the brain with intranasal mirtazapine mucoadhesive microemulsion.
Conclusions And Perspectives
Direct intranasal drug transportation to the brain has been highlighted as a potential strategy for addressing antidepressant therapy, because it would break through the bottleneck of the blood-brain barrier and enhance targeting ability. It is well-known that the progress of intranasal drug transportation benefits from nanocarrier-based formulations, however, although encouraging and tremendous developments have achieved, to explore and apply all kinds of drug carriers for antidepressant treatment by the intranasal route in clinics retains many challenges. Drugs in the intranasal delivery route are more sensitive for enzyme, acid, and hepatic metabolism than other routes. Moreover, the absorption and bioavailability of drugs can usually be influenced by rapid drug elimination, limited administration volume, and so on. In addition, the use of intranasal drugs is still at an early stage and far from clinical practice. As we know, esketamine nasal spray was recently approved as the first intranasal prescription medicine used for the treatment of depression. These findings corroborate that nose-to-brain drug delivery could provide a strong effective solution for treatment-resistant depression. Regulatory issues in safety and quality aspects need to be satisfied to translate these methods from research to the market. The pharmaceutical industry must be evolving and improving processes for manufacturing accurate and repeatable intranasal dose in the coming years. In this review, we introduced the absorption mechanism, advantages including large absorption surface area, good patient compliance, rapid and high drug permeability, bypassing of hepatic first-pass metabolism, potential direct drug delivery to the brain along the olfactory nerves, and limitations, including rapid drug elimination prompted by mucociliary clearance (5 mm/min for healthy humans), limited administration volume (25–200 ml), and the presence of enzymes that degrade in nasal drug delivery route (Lechanteur et al., 2017, 2019; Chen S. et al., ; Lechanteur and Evrard, 2020; Sabir et al., 2020; Taipaleenmaki and Stadler, 2020). Then, we systematically summarized the development of intranasal delivery carriers of antidepressants in clinical studies including nanogels, nanostructured lipid, liposomes nanoparticles, and nanoemulsions/microemulsion. Finally, recent progress, challenges, and future perspectives of intranasal delivery carriers in antidepressant treatment were discussed.
Statements
Author contributions
JX: conceptualization and writing—original draft preparation. JT: investigation and writing—original draft preparation. JW: supervision, writing—reviewing, and editing. All authors read and approved the final manuscript.
Funding
This work was supported by the National Natural Science Foundation of China (No. 62071413), the Hebei Natural Science Foundation (No. F2020203056), Hebei Social Science Foundation (HB16SH050), Hebei education department key project (No. ZD2020147), and the Graduate Education and Teaching Reform Project of Yanshan University, Novel Coronavirus Pneumonia Research Project of Yanshan University (Construction of Long-term Mechanism of Psychological Crisis Intervention in Novel Coronavirus Pneumonia—A Case study of Hebei Province).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbbottN. J.PatabendigeA.DolmanD. E. M.YusofS. R.BegleyD. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13–25. 10.1016/j.nbd.2009.07.030
2
AbouhusseinD. M. N.KhattabA.BayoumiN. A.MahmoudA. F.SakrT. M. (2018). Brain targeted rivastigmine mucoadhesive thermosensitive in situ gel: optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J. Drug Deliv. Sci. Technol. 43, 129–140. 10.1016/j.jddst.2017.09.021
3
AderibigbeB. A.NakiT. (2019). Chitosan-based nanocarriers for nose to brain delivery. Appl. Sci.9:2219. 10.3390/app9112219
4
AkelH.IsmailR.CsokaI. (2020). Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease. Eur. J. Pharm. Biopharm.148, 38–53. 10.1016/j.ejpb.2019.12.014
5
AlagusundaramM.ChengaiahB.GnanaprakashK.RamkanthS.ChettyC. M.DhachinamoorthiD. (2010). Nasal drug delivery system - an overview. Int. J. Res. Pharm. Sci.1, 454–465.
6
AlamM. I.BabootaS.AhujaA.AliM.AliJ.SahniJ. K.et al. (2014). Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int. J. Pharm. 470, 99–106. 10.1016/j.ijpharm.2014.05.004
7
AlexA. T.JosephA.ShaviG. V.RaoJ. V.UdupaN. (2014). Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv. 23, 2144–2153. 10.3109/10717544.2014.948643
8
AmbrusR.GieszingerP.GáspárR.Sztojkov-IvanovA.DuczaE.MárkiÁ.et al. (2020). Investigation of the absorption of nanosized lamotrigine containing nasal powder via the nasal cavity. Molecules25:1065. 10.3390/molecules25051065
9
AngeliE.NguyenT. T.JaninA.BousquetG. (2019). How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int. J. Mol. Sci. 21:22. 10.3390/ijms21010022
10
BachurinS. O.GavrilovaS. I.SamsonovaA.BarretoG. E.AlievG. (2018). Mild cognitive impairment due to Alzheimer disease: contemporary approaches to diagnostics and pharmacological intervention. Pharmacol. Res.129, 216–226. 10.1016/j.phrs.2017.11.021
11
BadheR. V.NipateS. S. (2020). Nasal bioadhesive drug delivery systems and their applications, in Bioadhesives in Drug Delivery, eds K. L. Mittal, I. S. Bakshi, and J. K. Narang (New Jersey, NJ: John Wiley and Sons), 259–305. 10.1002/9781119640240.ch10
12
BakriW. A.DonovanM. D.CuetoM.WuY.OrekieC.YangZ. (2018). Overview of intranasally delivered peptides: key considerations for pharmaceutical development. Expert Opin. Drug Deliv. 15, 991–1005. 10.1080/17425247.2018.1517742
13
BellJ. H.HartleyP. S.CoxJ. S. G. (1971). Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci. 60, 1559–1564. 10.1002/jps.2600601028
14
BentoA. P.GaultonA.HerseyA.BellisL. J.ChambersJ.DaviesM.et al. (2014). The ChEMBL bioactivity database: an update. Nucl. Acids Res. 42, D1083–D1090. 10.1093/nar/gkt1031
15
BergerW. E.GodfreyJ. W.SlaterA. L. (2007). Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin. Drug Deliv. 4, 689–701. 10.1517/17425247.4.6.689
16
BernackiJ.DobrowolskaA.NierwinskaK.MaleckiA. (2008). Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep.60, 600–622. 10.1111/j.1365-2249.2008.03826.x
17
BhandwalkarM. J.AvachatA. M. (2013). Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, pharmacodynamic evaluation. AAPS PharmSciTech14, 101–110. 10.1208/s12249-012-9893-1
18
BickerJ.AlvesG.FortunaA.FalcaoA. (2014). Blood–brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur. J. Pharm. Biopharm.87, 409–432. 10.1016/j.ejpb.2014.03.012
19
BrandG. (2006). Olfactory/trigeminal interactions in nasal chemoreception. Neurosci. Biobehav. Rev.30, 908–917. 10.1016/j.neubiorev.2006.01.002
20
BrozzettiL.SacchettoL.CecchiniM. P.AvesaniA.ZanussoG. (2020). Neurodegeneration-associated proteins in human olfactory neurons collected by nasal brushing. Front. Neurosci.14:145. 10.3389/fnins.2020.00145
21
BrunelleA.HiteM.HoR. J. Y.HoekmanJ. D.RelethfordJ. (2012). Nasal Drug Delivery Device. WO Patent WO2012119153 A2.
22
CaggianoM.KauerJ. S.HunterD. D. (1994). Globose basal cells are neuronal progenitors in the olfactory epithelium: a lineage analysis using a replication-incompetent retrovirus. Neuron13, 339–352. 10.1016/0896-6273(94)90351-4
23
ChaturvediM.KumarM.PathakK. (2011). A review on mucoadhesive polymer used in nasal drug delivery system. J. Adv. Pharm. Technol. Res. 2, 215–22210.4103/2231-4040.90876
24
ChenJ.JiangZ.XuW.SunT.ZhuangX.DingJ.et al. (2020). Spatiotemporally targeted nanomedicine overcomes hypoxia-induced drug resistance of tumor cells after disrupting neovasculature. Nano Lett. 20, 6191–6198. 10.1021/acs.nanolett.0c02515
25
ChenS.GuoH.CuiM.HuangR.SuR.QiW.et al. (2020). Interaction of particles with mucosae and cell membranes. Colloids Surf. Biointerfaces186:110657. 10.1016/j.colsurfb.2019.110657
26
ChoiJ. U.MaharjanR.PangeniR.JhaS. K.LeeN. K.KweonS.et al. (2020). Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. J. Control. Release322, 13–30. 10.1016/j.jconrel.2020.03.012
27
CostaC.MoreiraJ. N.AmaralM. H.LoboJ. M. S.SilvaA. C. (2019). Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J. Controlled Release295, 187–200. 10.1016/j.jconrel.2018.12.049
28
CraftS.RamanR.ChowT. W.RafiiM. S.SunC. K.RissmanR. A.et al. (2020). Safety efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol.77, 1099–1109.10.1001/jamaneurol.2020.1840
29
DandreaG. (2015). Quercetin: a flavonol with multifaceted therapeutic applications?Fitoterapia106, 256–271. 10.1016/j.fitote.2015.09.018
30
DhuriaS. V.HansonL. R.FreyW. H.II (2010). Frey II: intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654–1673. 10.1002/jps.21924
31
DiasR.MaliK.ShindeJ.HavaldarV.MaliR. (2010). Formulation and evaluation of thermoreversible mucoadhesive nasal gels of metoclopramide hydrochloride. Latin Am. J. Pharm.29, 354–361. 10.3109/10717540903447194
32
DingJ.ChenJ.GaoL.JiangZ.ZhangY.LiM.et al. (2019a). Engineered nanomedicines with enhanced tumor penetration. Nano Today29:100800. 10.1016/j.nantod.2019.100800
33
DingJ.FengX.JiangZ.XuW.GuoH.ZhuangX.et al. (2019b). Polymer-mediated penetration-independent cancer therapy. Biomacromolecules20, 4258–4271. 10.1021/acs.biomac.9b01263
34
DjupeslandP. G. (2013). Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv. Transl. Res. 3, 42–62. 10.1007/s13346-012-0108-9
35
DjupeslandP. G.MessinaJ. C.MahmoudR. A. (2014). The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv. 5, 709–733. 10.4155/tde.14.41
36
DruliskawaZ.DorotkiewiczjachA. (2010). Liposomes as delivery systems for antibiotics. Int. J. Pharm. 387, 187–198. 10.1016/j.ijpharm.2009.11.033
37
DuringM. J.CaoL.ZuzgaD. S.FrancisJ. S.FitzsimonsH. L.JiaoX.et al. (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173–1179. 10.1038/nm919
38
DuvvuriS.MajumdarS.MitraA. K. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 3, 45–56. 10.1517/14712598.3.1.45
39
ErdőF.BorsL. A.FarkasD.BajzaÁ.GizurarsonS. (2018). Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 143, 155–170. 10.1016/j.brainresbull.2018.10.009
40
Fonseca-SantosB.GremiãoM. P.ChorilliM. (2015). Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. Int. J. Nanomedicine10, 4981–5003. 10.2147/IJN.S87148
41
FortunaA.AlvesG.SerralheiroA.SousaJ.FalcaoA. (2014). Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur. J. Pharm. Biopharm.88, 8–27. 10.1016/j.ejpb.2014.03.004
42
GangerS.SchindowskiK. (2018). Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics10:116. 10.3390/pharmaceutics10030116
43
GholizadehH.ChengS.PozzoliM.MesserottiE.TrainiD.YoungP. M.et al. (2019). Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opin. Drug Deliv. 16, 453–466. 10.1080/17425247.2019.1597051
44
GlahnD. C.CurranJ. E.WinklerA. M.CarlessM. A.KentJ. W.CharlesworthJ.et al. (2012). High dimensional endophenotype ranking in the search for major depression risk genes. Biol. Psychiatry71, 6–14. 10.1016/j.biopsych.2011.08.022
45
Gomes dos ReisL.GhadiriM.YoungP.TrainiD. (2020). Nasal powder formulation of tranexamic acid and hyaluronic acid for the treatment of epistaxis. Pharm. Res. 37:186. 10.1007/s11095-020-02913-w
46
GraffC. L.PollackG. M. (2005). Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci. 94, 1187–1195. 10.1002/jps.20318
47
GrinbergY. Y.ZitzowL. A.KraigR. P. (2017). Intranasally administered IGF-1 inhibits spreading depression in vivo. Brain Res. 1677, 47–57. 10.1016/j.brainres.2017.09.022
48
HaqueS.Shadab FazilM.KumarM.SahniJ. K.AliJ.BabootaS. (2012). Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr. Polym.89, 72–79. 10.1016/j.carbpol.2012.02.051
49
HaqueS.ShadabM. D.SahniJ. K.AliJ.BabootaS. (2014). Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J. Psychiatr. Res. 48, 1–12. 10.1016/j.jpsychires.2013.10.011
50
HeH.LinD.SunJ.HeX.WangT.FangY.et al. (2020). An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholera toxin-like chimeric protein. J. Control. Release322, 509–518. 10.1016/j.jconrel.2020.03.027
51
HuangC. H.KimuraR.NassarR. B.HussainA. A. (1985). Mechanism of nasal absorption of drugs I: physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J. Pharm. Sci. 74, 608–611. 10.1002/jps.2600740605
52
HuangJ.GarmiseR. J.CrowderT. M.MarK.HwangC. R.HickeyA. J.et al. (2004). A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine23, 794–801. 10.1016/j.vaccine.2004.06.049
53
IllumL. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eu. J. Pharm. Sci.11, 1–18. 10.1016/S0928-0987(00)00087-7
54
InoueD.FurubayashiT.TanakaA.SakaneT.SuganoK. (2020). Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats. Eur. J. Pharm. Biopharm.149, 145–153. 10.1016/j.ejpb.2020.02.004
55
InoueD.KimuraS.KiriyamaA.KatsumiH.YamamotoA.OgawaraK.-,i, Higaki, K.et al. (2018). Quantitative estimation of the effect of nasal mucociliary function on in vivo absorption of norfloxacin after intranasal administration to rats. Mol. Pharm. 15, 4462–4469. 10.1021/acs.molpharmaceut.8b00464
56
IslamS. U.ShehzadA.AhmedM. B.LeeY. S. (2020). Intranasal delivery of nanoformulations: a potential way of treatment for neurological disorders. Molecules25:1929. 10.3390/molecules25081929
57
JadhavK. R.GambhireM. N.ShaikhI. M.KadamV. J.PisalS. S. (2007). Drug delivery system-factors affecting and applications. Curr. Drug Ther. 2, 27–38. 10.2174/157488507779422374
58
JiangL.LiS.ZhengJ.LiY.HuangH. (2019). Recent progress in microfluidic models of the blood-brain barrier. Micromachines10:375. 10.3390/mi10060375
59
JoganiV.ShahP.MishraP.MishraA. K.MisraA. (2008). Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis. Assoc. Disord. 22, 116–124. 10.1097/WAD.0b013e318157205b
60
JohnsonN. J.HansonL. R.FreyW. H. (2010). Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol. Pharm. 7, 884–893. 10.1021/mp100029t
61
JohnstonM.ZakharovA.PapaiconomouC.SalmasiG.ArmstrongD. (2004). Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 1:2. 10.1186/1743-8454-1-2
62
JonesL.DownieL. E.KorbD. R.BenitezdelcastilloJ. M.DanaR.DengS. X.et al. (2017). TFOS DEWS II management and therapy report. Ocular Surface15, 575–628. 10.1016/j.jtos.2017.05.006
63
JoshiH. M.BhumkarD. R.JoshiK.PokharkarV.SastryM. (2006). Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir22, 300–305. 10.1021/la051982u
64
JullaphantT.NakpengT.SrichanaT. (2009). Montelukast nasal spray: formulation development and in vitro evaluation. Pharm. Dev. Technol. 24, 494–503. 10.1080/10837450.2018.1514523
65
KanekoK.OsmanN.CariniV.ScagnettiG.SaleemI. (2020). Overview of the advantages and disadvantages of different mucosal sites for the delivery of nanoparticles, in Mucosal Delivery of Drugs and Biologics in Nanoparticles, eds P. Muttil, and N. K. Kunda (Cham: Springer International Publishing). 10.1007/978-3-030-35910-2_3
66
KangmielerJ. J.OsswaldC. R.MielerW. F. (2014). Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin. Drug Deliv. 11, 1647–1660. 10.1517/17425247.2014.935338
67
KanojiaG.HaveR. T.SoemaP. C.FrijlinkH.AmorijJ. P.KerstenG. (2017). Developments in the formulation and delivery of spray dried vaccines. Hum. Vaccin. Immunother. 13, 2364–2378. 10.1080/21645515.2017.1356952
68
KashyapK.ShuklaR. (2019). Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges. Curr. Drug Deliv. 16, 887–901. 10.2174/1567201816666191029122740
69
KaurP.GargT.VaidyaB.PrakashA.RathG.GoyalA. (2014). Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: behavioral and biochemical assessment. J. Drug Target23, 1–12. 10.3109/1061186X.2014.994097
70
KayeR. S.PurewalT. S.AlparO. H. (2009). Development and testing of particulate formulations for the nasal delivery of antibodies. J. Control. Release135, 127–135. 10.1016/j.jconrel.2008.11.009
71
KhanA. R.LiuM.KhanM. W.ZhaiG. (2017). Progress in brain targeting drug delivery system by nasal route. J. Control. Release268, 364–389. 10.1016/j.jconrel.2017.09.001
72
KitiyodomS.KaewmalunS.NittayasutN.SukthamK.SurassmoS.NamdeeK.et al. (2019). The potential of mucoadhesive polymer in enhancing efficacy of direct immersion vaccination against Flavobacterium columnare infection in tilapia. Fish Shellfish Immunol. 86, 635–640. 10.1016/j.fsi.2018.12.005
73
KrauzeM. T.ForsayethJ.ParkJ. W.BankiewiczK. S. (2006). Real-time imaging and quantification of brain delivery of liposomes. Pharm. Res. 23, 2493–250410.1007/s11095-006-9103-5
74
KumarA.PandeyA. N.JainS. K. (2016). Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 23, 671–683. 10.3109/10717544.2014.920431
75
LaffleurF.KeckeisV. (2020). Advances in drug delivery systems: work in progress still needed?Int. J. Pharm.2:100050. 10.1016/j.ijpx.2020.100050
76
LechanteurA.EvrardB. (2020). Influence of composition and spray-drying process parameters on carrier-free DPI properties and behaviors in the lung: a review. Pharmaceutics12:55. 10.3390/pharmaceutics12010055
77
LechanteurA.EvrardB.PielG. (2019). Assessment of the feasibility to develop a fast and easy reproducible 3D bronchial model growing at the air-liquid interface: which critical culture parameters must be controlled?Eur. J. Pharm. Biopharm.144, 2–10. 10.1016/j.ejpb.2019.09.001
78
LechanteurA.NevesJ.SarmentoB. (2017). The role of mucus in cell-based models used to screen mucosal drug delivery. Adv. Drug Deliv. Rev. 124, 50–63. 10.1016/j.addr.2017.07.019
79
LeeS. A.HongS. S.HanX. H.HwangJ. S.OhG. J.LeeK. S.et al. (2005). Piperine from the fruits of piper longum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem. Pharm. Bull.53, 832–835. 10.1248/cpb.53.832
80
LengyelM.KallaiszaboN.AntalV.LakiA. J.AntalI. (2019). Microparticles, microspheres, and microcapsules for advanced drug delivery. Sci. Pharm. 87:20. 10.3390/scipharm87030020
81
LeopoldD. A. (1988). The relationship between nasal anatomy and human olfaction. Laryngoscope98, 1232–1238. 10.1288/00005537-198811000-00015
82
LiL.NandiI.KimK. H. (2002). Development of an ethyl laurate-based microemulsion for rapid-onset intranasal delivery of diazepam. Int. J. Pharm. 237, 77–85. 10.1016/S0378-5173(02)00029-7
83
LiS.ZhangT.XuW.DingJ.YinF.XuJ.et al. (2018). Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics8, 1361–1375. 10.7150/thno.18299
84
LiY.FanX.LiW.YangP.ZhangH.TangD.et al. (2018). Metoclopramide nasal spray in vitro evaluation and in vivo pharmacokinetic studies in dogs. Pharm. Dev. Technol. 23, 275–281. 10.1080/10837450.2017.1316734
85
LoirapastorizaC.TodoroffJ.VanbeverR. (2014). Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev. 75, 81–91. 10.1016/j.addr.2014.05.017
86
MaculottiK.GentaI.PeruginiP.ImamM.Bernkop-SchnürchA.PavanettoF. (2005). Preparation and in vitro evaluation of thiolated chitosan microparticles. J. Microencapsul. 22, 459–470. 10.1080/02652040500162220
87
MansuriS.KesharwaniP.JainK.TekadeR. K.JainN. K. (2016). Mucoadhesion: a promising approach in drug delivery system. React. Funct. Polym. 100, 151–172. 10.1016/j.reactfunctpolym.2016.01.011
88
MartinP. D.WarwickM. J.DaneA. L.HillS. J.GilesP. B.PhillipsP. J.et al. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25, 2822–2835. 10.1016/S0149-2918(03)80336-3
89
MasonT. G.WilkingJ. N.MelesonK.ChangC. B.GravesS. M. (2006). Nanoemulsions: formation, structure, physical properties. J. Phys.18:079001. 10.1088/0953-8984/19/7/079001
90
MathiasN. R.HussainM. A. (2010). Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J. Pharm. Sci. 99, 1–20. 10.1002/jps.21793
91
MehtaS. K.KaurG.BhasinK. K. (2008). Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: effect on microstructure and physical parameters. Pharm. Res. 25, 227–236. 10.1007/s11095-007-9355-8
92
MennesonS.MénicotS.MalbertC.-H.MeuriceP.SerrandY.NoirotV.et al. (2020). Neuromodulatory and possible anxiolytic-like effects of a spice functional food ingredient in a pig model of psychosocial chronic stress. J. Funct. Foods64:103599. 10.1016/j.jff.2019.103599
93
MistryA.StolnikS.IllumL. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 379, 146–157. 10.1016/j.ijpharm.2009.06.019
94
MorrisonE. E.CostanzoR. M. (1990). Morphology of the human olfactory epithelium. J. Comp. Neurol.297:1–13. 10.1002/cne.902970102
95
MouezM. A.ZakiN. M.MansourS.GeneidiA. S. (2014). Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. Eur. J. Pharm. Sci.51, 59–66. 10.1016/j.ejps.2013.08.029
96
MuchowM.MaincentP.MullerR. H. (2008). Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34, 1394–1405. 10.1080/03639040802130061
97
MusumeciT.BonaccorsoA. (2019). Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview. Pharmaceutics11:118. 10.3390/pharmaceutics11030118
98
NaikA. A.NairH. A. (2014). Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. Biomed Res. Int. 2014:847547. 10.1155/2014/847547
99
NidhiS.ShivB.PramodK. S. (2019). Recent advances and novel approaches for nose to brain drug delivery for treatment of migraine. Drug Deliv. Lett. 9, 182–198. 10.2174/2210303109666190508083142
100
ObrienF. E.DinanT. G.GriffinB. T.CryanJ. F. (2012). Interactions between antidepressants and P-glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 165, 289–312. 10.1111/j.1476-5381.2011.01557.x
101
OlearyO. F.DinanT. G.CryanJ. F. (2015). Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur. J. Pharmacol. 753, 32–50. 10.1016/j.ejphar.2014.07.046
102
PandeyY. R.KumarS.GuptaB. K.AliJ.BabootaS. (2016). Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation. Nanotechnology27:025102. 10.1088/0957-4484/27/2/025102
103
PatelM. M.PatelB. M. (2017). Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs31, 109–133. 10.1007/s40263-016-0405-9
104
PenttiläM.PoulsenP.HollingworthK.HolmströmM. (2000). Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin. Exp. Allergy30, 94–102. 10.1046/j.1365-2222.2000.00695.x
105
PiresP. C.SantosA. O. (2018). Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J. Control. Release270, 89–100. 10.1016/j.jconrel.2017.11.047
106
PripremA.ChonpathompikunlertP.SutthiparinyanontS.WattanathornJ. (2011). Antidepressant and cognitive activities of intranasal piperine-encapsulated liposomes. Adv. Biosci. Biotechnol.2, 108–116. 10.4236/abb.2011.22017
107
PripremA.WatanatornJ.SutthiparinyanontS.PhachonpaiW.MuchimapuraS. (2008). Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine4, 70–78. 10.1016/j.nano.2007.12.001
108
ProschakE.HeitelP.KalinowskyL.MerkD. (2017). Opportunities and challenges for fatty acid mimetics in drug discovery. J. Med. Chem. 60, 5235–5266. 10.1021/acs.jmedchem.6b01287
109
QianS.WongY. C.ZuoZ. (2014). Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int. J. Pharm.468, 272–282. 10.1016/j.ijpharm.2014.04.015
110
QiuH.GuoH.LiD.HouY.KuangT.DingJ. (2020). Intravesical hydrogels as drug reservoirs. Trends Biotechnol. 38, 579–583. 10.1016/j.tibtech.2019.12.012
111
QuintanaD. S.WestlyeL. T.RustanØ. G.TesliN.PoppyC. L.SmevikH.et al. (2015). Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment. Transl. Psychiatry5:e602. 10.1038/tp.2015.93
112
RohmM.CarleS.MaiglerF.FlammJ.KramerV.MavoungouC.et al. (2017). A comprehensive screening platform for aerosolizable protein formulations for intranasal and pulmonary drug delivery. Int. J. Pharm. 532, 537–546. 10.1016/j.ijpharm.2017.09.027
113
RohrerJ.LupoN.BernkopschnurchA. (2018). Advanced formulations for intranasal delivery of biologics. Int. J. Pharm. 553, 8–20. 10.1016/j.ijpharm.2018.10.029
114
SabirF.IsmailR.CsokaI. (2020). Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook. Drug Discov. Today25, 185–194. 10.1016/j.drudis.2019.10.005
115
SaeediM.EslamifarM.KhezriK.DizajS. M. (2019). Applications of nanotechnology in drug delivery to the central nervous system. Biomed. Pharm.111, 666–67510.1016/j.biopha.2018.12.133
116
SaladeL.WauthozN.GooleJ.AmighiK. (2019). How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int. J. Pharm. 561, 47–65. 10.1016/j.ijpharm.2019.02.026
117
SharmaA.SharmaU. S. (1997). Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154, 123–140. 10.1016/S0378-5173(97)00135-X
118
SharmaG.MishraA. K.MishraP.MisraA. (2009). Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies. AAPS PharmSciTech10, 1321–1330. 10.1208/s12249-009-9329-8
119
ShettyN.CipollaD.ParkH.ZhouQ. T. (2020). Physical stability of dry powder inhaler formulations. Expert Opin. Drug Deliv. 17, 77–96. 10.1080/17425247.2020.1702643
120
ShiX.MiaoW.PangD.WuJ.TongQ.LiJ.et al. (2020). Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. Biomater. Sci. 8, 1290–1297. 10.1039/C9BM01750J
121
SindhuP.KumarS.IqbalB.AliJ.BabootaS. (2018). Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. J. Psychiatr. Res. 99, 83–95. 10.1016/j.jpsychires.2018.01.015
122
SinghD. N.RashidM.HallanS. S.MehraN. K.PrakashA.MishraN. (2015). Pharmacological evaluation of nasal delivery of selegiline hydrochloride-loaded thiolated chitosan nanoparticles for the treatment of depression. Artif. Cells Nanomed. Biotechnol.44, 865–877. 10.3109/21691401.2014.998824
123
SinghR. M. P.KumarA.PathakK. (2013). Thermally triggered mucoadhesive in situ gel of loratadine: β-cyclodextrin complex for nasal delivery. AAPS PharmSciTech14, 412–42410.1208/s12249-013-9921-9
124
SinghY.MeherJ. G.RavalK.KhanF. A.ChaurasiaM.JainN. K.et al. (2017). Nanoemulsion: Concepts, development and applications in drug delivery. J. Control. Release252, 28–49. 10.1016/j.jconrel.2017.03.008
125
SintovA.LevyH. V.BotnerS. (2010). Systemic delivery of insulin via the nasal route using a new microemulsion system: in vitro and in vivo studies. J. Control. Release148, 168–176. 10.1016/j.jconrel.2010.08.004
126
SunC.DingY.ZhouL.ShiD.SunL.WebsterT. J.et al. (2017). Noninvasive nanoparticle strategies for brain tumor targeting. Nanomedicine13, 2605–2621. 10.1016/j.nano.2017.07.009
127
TaipaleenmakiE.StadlerB. (2020). Recent advancements in using polymers for intestinal mucoadhesion and mucopenetration. Macromol. Biosci. 20:1900342. 10.1002/mabi.201900342
128
TalegaonkarS.MishraP. R. (2004). Intranasal delivery: an approach to bypass the blood brain barrier. Indian J. Pharmacol. 36, 140–147.
129
TangF.HartzA. M. S.BauerB. (2017). Drug-resistant epilepsy: multiple hypotheses, few answers. Front. Neurol. 8:301. 10.3389/fneur.2017.00301
130
ThakkarH.PatelA. A.ChauhanN. P. (2013). Intranasal mucoadhesive microemulsion of mirtazapine: pharmacokinetic and pharmacodynamic studies. Asian J. Pharm.7:36. 10.4103/0973-8398.110934
131
ThorneR. G.FreyW. H. (2001). Delivery of neurotrophic factors to the central nervous system. Clin. Pharmacokinet40, 907–946. 10.2165/00003088-200140120-00003
132
ThorneR. G.PronkG. J.PadmanabhanV.FreyW. H. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience127, 481–496. 10.1016/j.neuroscience.2004.05.029
133
TongG.QinN.SunL. (2017). Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. J. Saudi Pharm. Soc.25, 844–851. 10.1016/j.jsps.2016.12.003
134
TrangsrudA. J.WhitakerA. L.SmallR. E. (2002). Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy22, 1458–1467. 10.1592/phco.22.16.1458.33692
135
UgwokeM. I.SamE.van Den MooterG.VerbekeN.KingetR. (1999). Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: influence of drug-loading on in vitro and in vivo release in rabbits. Int. J. Pharm. 181, 125–138. 10.1016/S0378-5173(99)00018-6
136
VenereauE.de LeoF.MezzapelleR.CarecciaG.MuscoG.BianchiM. E. (2016). HMGB1 as biomarker and drug target. Pharmacol. Res.111, 534–544. 10.1016/j.phrs.2016.06.031
137
VitorinoC.SilvaS.BickerJ.FalcãoA.FortunaA. (2019). Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. Drug Discov. Today24, 1911–1923. 10.1016/j.drudis.2019.06.001
138
VllasaliuD.Exposito-HarrisR.HerasA.CasettariL.GarnettM.IllumL.et al. (2010). Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 400, 183–193. 10.1016/j.ijpharm.2010.08.020
139
VyasT. K.BabbarA. K.SharmaR. K.MisraA. (2005). Intranasal mucoadhesive microemulsions of zolmitriptan: preliminary studies on brain-targeting. J. Drug Target. 13, 317–324. 10.1080/10611860500246217
140
VyasT. K.BabbarA. K.SharmaR. K.SinghS.MisraA. (2006a). Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech7, E49–E57. 10.1208/pt070108
141
VyasT. K.BabbarA. K.SharmaR. K.SinghS.MisraA. (2006b). Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J. Pharm. Sci. 95, 570–580. 10.1002/jps.20480
142
WangS.SunY.ZhangJ.CuiX.XuZ.DingD.et al. (2020). Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics. Front. Pharmacol. 11:230. 10.3389/fphar.2020.00230
143
WangW.SunC.MaoL.MaP.LiuF.YangJ.et al. (2016). The biological activities, chemical stability, metabolism and delivery systems of quercetin: a review. Trends Food Sci. Technol.56, 21–38. 10.1016/j.tifs.2016.07.004
144
WangZ.ChowM. S. (2014). Overview and appraisal of the current concept and technologies for improvement of sublingual drug delivery. Ther. Deliv. 5, 807–816. 10.4155/tde.14.50
145
WongC. Y.AlsalamiH.DassC. R. (2017). Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. J. Control. Release264, 247–275. 10.1016/j.jconrel.2017.09.003
146
YamamotoY.DanhofM. M.de LangeE. C. (2017). Microdialysis: the key to physiologically based model prediction of human CNS target site concentrations. AAPS J.19, 891–909. 10.1208/s12248-017-0050-3
147
ZhangM.ZangX.WangM.LiZ.QiaoM.HuH.et al. (2019). Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J. Mater. Chem. B7, 2421–2433. 10.1039/C9TB00170K
148
ZhangQ.JiangX.JiangW.LuW.SuL.ShiZ. (2004). Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 275, 85–96. 10.1016/j.ijpharm.2004.01.039
149
ZhangY.YuJ.RenK.ZuoJ.DingJ.ChenX. (2019). Thermosensitive hydrogels as scaffolds for cartilage tissue engineering. Biomacromolecules20, 1478–1492. 10.1021/acs.biomac.9b00043
Summary
Keywords
intranasal route, antidepressants, delivery carrier, design and application, challenges and future perspectives
Citation
Xu J, Tao J and Wang J (2020) Design and Application in Delivery System of Intranasal Antidepressants. Front. Bioeng. Biotechnol. 8:626882. doi: 10.3389/fbioe.2020.626882
Received
07 November 2020
Accepted
27 November 2020
Published
21 December 2020
Volume
8 - 2020
Edited by
Jianxun Ding, Chinese Academy of Sciences, China
Reviewed by
Yue Zheng, First Hospital of Qinhuangdao, China; Bing Zhou, Jilin University, China
Updates
Copyright
© 2020 Xu, Tao and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jidong Wang wangjidong@ysu.edu.cn
This article was submitted to Biomaterials, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.